OMERS Administration Corp’s AN2 Therapeutics ANTX Stock Holding History

OMERS Administration Corp’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,800	Closed	-$54K	–	922
2026 Q1	$54K	Buy	+15,800	New	+$32.6K	﹤0.01%	1058

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

OMERS Administration Corp's ANTX Position: Q2 2026 in Review

OMERS Administration Corp sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 15,800 shares — an estimated $54K sold.

OMERS Administration Corp first reported a position in ANTX in Q1 2026 and held it in 1 quarter. The position peaked at $54K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

OMERS Administration Corp reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
OMERS Administration Corp sold 15,800 AN2 Therapeutics shares in Q2 2026, an estimated $54K.
OMERS Administration Corp first reported a position in AN2 Therapeutics in Q1 2026 and held it in 1 quarter.
OMERS Administration Corp's AN2 Therapeutics position peaked at $54K in Q1 2026.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.